文献速递抗菌药物管理药物不良反应与药物警戒

口服β-内酰胺类治疗复杂性尿路感染:系统综述及与TMP/SMX和氟喹诺酮类的点-反点比较

Oral β-Lactams for Complicated Urinary Tract Infections: A Systematic Review and Point-Counterpoint Comparison With Trimethoprim/Sulfamethoxazole and Fluoroquinolones.
PubMed 文献 · Pharmacotherapy · 2026-01-01

结果显示,适当剂量下口服β-内酰胺类疗效与FQs和TMP/SMX相当,高生物利用度药物成功率超过90%,但剂量不足时复发率更高;不良事件发生率较低(1.3% vs 2.3% vs 5.7%)。

要点

  • 高口服生物利用度β-内酰胺类(如头孢氨苄、头孢泊肟、头孢呋辛、阿莫西林/克拉维酸)适当剂量下治疗cUTI成功率超过90%。
  • 口服β-内酰胺类不良事件发生率1.3%,低于FQs的2.3%和TMP/SMX的5.7%。
  • 剂量不足时口服β-内酰胺类复发率更高,需关注给药频次和生物利用度变异。

核心结论

  • 部分口服β-内酰胺类适当剂量下治疗cUTI和菌血症性UTI的疗效与FQs或TMP/SMX相当,可作为合适患者的有效替代选择。

主要发现

  • 口服β-内酰胺类适当剂量下治疗cUTI(包括菌血症性UTI)疗效与FQs和TMP/SMX相当。
  • 高口服生物利用度β-内酰胺类(如头孢氨苄、头孢泊肟、头孢呋辛、阿莫西林/克拉维酸)成功率超过90%,但剂量不足时复发率更高。
  • 口服β-内酰胺类不良事件发生率为1.3%,低于FQs的2.3%和TMP/SMX的5.7%。
  • 口服β-内酰胺类可能存在给药频繁、生物利用度变异和药敏试验挑战等局限性。

关键数值与推荐

  • 高口服生物利用度β-内酰胺类适当剂量下成功率超过90%。
  • 不良事件发生率:口服β-内酰胺类1.3%,FQs 2.3%,TMP/SMX 5.7%。

临床怎么用

  • 在适当选择的患者中,可考虑将高口服生物利用度β-内酰胺类作为cUTI和菌血症性UTI的替代治疗,需确保 optimal 剂量以避免复发。
  • 关注给药频次和生物利用度变异,必要时进行治疗药物监测或选择生物利用度稳定的品种。

局限性

  • 仅纳入观察性研究,缺乏随机对照试验证据。
  • 研究设计 and 结局报告异质性大,采用叙述性综合。
  • 需随机试验确认观察性发现并明确最佳剂量策略和缩短疗程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rising resistance and toxicity concerns with fluoroquinolones (FQs) and trimethoprim/sulfamethoxazole (TMP/SMX) have prompted interest in oral β-lactams as alternatives for complicated urinary tract infections (cUTIs). This review evaluates the effectiveness, safety, and pharmacokinetic (PK) considerations of oral β-lactams compared to FQs and TMP/SMX in these clinical contexts. A structured point-counterpoint discussion explores their role in antimicrobial stewardship and patient-centered therapy. METHODS: A systematic PubMed search identified studies published between January 2000 and December 2025. Eligible studies included randomized trials and observational cohort studies evaluating clinical effectiveness, microbiological outcomes, or safety of oral β-lactams for cUTIs or bacteremic UTI compared with FQs or TMP/SMX. Outcomes of interest included treatment success, recurrence, adverse events, and PK considerations. Excluded studies involved special populations, nontraditional agents, or infections outside the scope of cUTI. Data were synthesized narratively due to heterogeneity in study design and outcome reporting. RESULTS: Seventeen observational studies met the inclusion criteria. Oral β-lactams demonstrated comparable effectiveness to FQs and TMP/SMX for cUTIs, including bacteremic UTI, when dosed appropriately. Oral β-lactams with high oral bioavailability (e.g., cephalexin, cefpodoxime, cefuroxime, amoxicillin/clavulanate), showed success rates exceeding 90%, but recurrence was higher when underdosed. Oral β-lactams had lower adverse event rates (1.3%) compared to FQs (2.3%) and TMP/SMX (5.7%), but may carry limitations including frequent dosing, variable bioavailability, and susceptibility testing challenges. CONCLUSIONS: Although not traditionally recognized as first-line therapy, select oral β-lactams demonstrated effectiveness comparable to FQs or TMP/SMX for cUTIs and bacteremic UTI and can serve as effective alternatives in appropriately selected patients. When optimally dosed, these β-lactams achieve comparable outcomes with favorable safety profiles and antimicrobial stewardship advantages. Randomized trials are needed to confirm these observational findings and to better define optimal dosing strategies and shorter treatment durations.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Kunz Coyne AJ, Bouchard J, Durham SH, et al. Oral β-Lactams for Complicated Urinary Tract Infections: A Systematic Review and Point-Counterpoint Comparison With Trimethoprim/Sulfamethoxazole and Fluoroquinolones. Pharmacotherapy. 2026. PMID: 41693075. doi:10.1002/phar.70118

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。